Estamos na era de "personalizar" os tratamentos do cancro, o que só poderá acontecer se compreendermos melhor o modo como os tumores se desenvolvem e comportam durante a terapêutica. Seguindo esta linha de raciocínio, um grupo de investigadores, liderado por Ana Teresa Maia, docente da UAlg e investigadora do Centro de Investigação em Tecnologias e Serviços de Saúde (CINTESIS), acaba de publicar um artigo na revista "npj Breast Cancer" que identifica um novo biomarcador para prognóstico em pacientes com cancro da mama.
The health of the population is crucial for the development of society. Unfortunately, current health systems are under increasing pressure, greatly aggravated by the Covid-19 pandemic, which, consequently, has made the work of health professionals in the field of oncology difficult. Cancer is the second leading cause of death worldwide and it is estimated that in 2040 there will be 28.4 million new cases of cancer worldwide.
A saúde da população é crucial para o desenvolvimento da sociedade. Infelizmente, os sistemas de saúde actuais estão sob crescente pressão, muito agravada pela pandemia de Covid-19 que, consequentemente, veio dificultar o trabalho aos profissionais de saúde na área da oncologia. O cancro é a segunda causa de morte a nível mundial e estima-se que em 2040 ocorrerão 28,4 milhões de novos casos de cancro em todo o mundo.
The paper entitled "A panel of intestinal differentiation markers (CDX2, GPA33, and LI‑cadherin) identifies gastric cancer patients with favourable prognosis" from the Differentiation & Cancer group at i3S has won the first edition of "Prémio Cancro Gástrico IPO do Porto", an award for the best article in gastric cancer research published in the past 2 years assigned by IPO Porto. The award ceremony will take place at IPO Porto on May 31st, 2021.
O artigo intitulado "A panel of intestinal differentiation markers (CDX2, GPA33, and LI‑cadherin) identifies gastric cancer patients with favourable prognosis" do grupo Differentiation & Cancer, no i3S, foi galardoado com a primeira edição do "Prémio Cancro Gástrico IPO do Porto", um prémio para o melhor artigo em investigação em cancro gástrico publicado nos últimos 2 anos e atribuído pelo IPO do Porto. A cerimónia de entrega do prémio terá lugar no IPO do Porto, no próximo dia 31 de Maio.
Poor survival and treatment failure of patients with cancer are mainly due to therapy resistance. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis were used to characterise the impact of TRIB2 on the expression of genes and develop pharmacological strategies to revert these TRIB2-mediated changes, thereby overcoming therapy resistance.
Poor survival and treatment failure of patients with cancer are mainly due to therapy resistance. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis were used to characterise the impact of TRIB2 on the expression of genes and develop pharmacological strategies to revert these TRIB2-mediated changes, thereby overcoming therapy resistance.
Joana Maia1,2, Andreia Hanada Otake1,3, Juliana Poças4,5,6, Ana Sofia Carvalho7, Hans Christian Beck8, Ana Magalhães4,5, Rune Matthiesen7, Maria Carolina Strano Moraes1 and Bruno Costa-Silva1
1-Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, Portugal
2-Graduate Program in Areas of Basic and Applied Biology, University of Porto, Porto, Portugal